Evaluation of the Impact of Vitrification on Oocytes
|ClinicalTrials.gov Identifier: NCT01223118|
Recruitment Status : Completed
First Posted : October 18, 2010
Last Update Posted : January 23, 2013
|Condition or disease||Intervention/treatment||Phase|
|Fertilization||Procedure: Vitrification and PGD||Not Applicable|
This study will recruit patients from the NY/NJ/CT/eastern PA area only.
Cryopreservation of human oocytes has a great potential to preserve or extend fertility in the face of disease whose treatment would result in a loss of ovarian function. (malignancy, severe autoimmune disease, etc.). It would also provide a means of quarantining oocytes to be used in oocyte donation to provide the lowest possible risk of infection.
There are two methods for storage of oocytes: slow freezing or vitrification. Slow freezing is the conventional method and has been successfully used for embryos since 1983 and more recently for oocytes. Recent reports indicate that vitrification may be more successful than slow freezing. However, the technique has not been rigorously validated to date. The aim of this study is to determine the rate of cryosurvival of mature oocytes following vitrification, and to then compare the reproductive potential of vitrified oocytes relative to those which have not been cryopreserved.
Patients will undergo ovarian stimulation for in vitro fertilization (IVF) according to the protocol recommended by their primary doctor. After retrieval, mature oocytes will be divided in half. One half will undergo vitrification, immediate thaw and intracytoplasmic sperm injection (ICSI). The other half will undergo just ICSI. All embryos will then develop on identical culture until day 3 or day 5. Prior to transfer, the best embryo from each group will undergo biopsy for genetic fingerprinting. The patient will have a 2 embryo transfer (one from each group). All extra embryos will be biopsied for pre-implantation genetic diagnosis (PGD) prior to being cryopreserved. If the patient becomes pregnant, we will follow up with an additional blood draw at approximately 9 weeks gestation and buccal swabs after the delivery of the infant(s).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||120 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluation of the Impact of Vitrification on the Reproductive Performance and Potential of Human Oocytes|
|Study Start Date :||August 2010|
|Actual Primary Completion Date :||July 2012|
|Actual Study Completion Date :||July 2012|
Experimental: Oocyte Vitrification
Each patient will have oocytes randomized into two groups immediately after retrieval. Half of oocytes will be vitrified, thawed and inseminated. The other half will be inseminated only. All embryos will be biopsied for PGD prior to transfer and one embryo from each group will be transferred (vitrification and control groups). Following delivery, buccal swabs will be collected on all infants.
Procedure: Vitrification and PGD
Half of the oocytes retrieved from each patient will undergo vitrification, immediate thaw and insemination. All embryos will undergo biopsy for PGD prior to transfer.
- Aneuploidy Rate (evaluation of whether embryo is chromosomally normal) [ Time Frame: 1 year ]Compare the rate of chromosomally-abnormal embryos among embryos originating from vitrified oocytes versus embryos originating from fresh/control oocytes.
- Delivery rates [ Time Frame: 1 year ]All embryos will be biopsied prior to transfer and DNA samples will be collected from all infants. Compare embryonic and infant DNA to evaluate whether the live birth resulted from a vitrified or a fresh/control oocyte.
- Paired Sustained Implantation Rate (number of viable fetuses beyond the first trimester per embryo transferred) [ Time Frame: 1 year ]Among patients with a paired two blastocyst transfer, compare the implantation rate of embryos originating from vitrified oocytes versus embryos originating from fresh/control oocytes.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01223118
|United States, New Jersey|
|Reproductive Medicine Associates of New Jersey|
|Morristown, New Jersey, United States, 07960|
|United States, Pennsylvania|
|Reproductive Medicine Assoicates of PA at Lehigh Valley|
|Allentown, Pennsylvania, United States, 18104|
|Principal Investigator:||Richard T Scott, MD||Reproductive Medicine Associates of New Jersey|